Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease

This study has been completed.
Sponsor:
Collaborators:
University Hospital, Basel, Switzerland
University of Lausanne Hospitals
Swiss IBD Cohort Study
MSD Merck Sharp & Dohme AG
Information provided by:
University of Bern
ClinicalTrials.gov Identifier:
NCT01473927
First received: November 3, 2011
Last updated: March 11, 2014
Last verified: March 2014
  Purpose

Background Determining disease activity in IBD is sometimes difficult and, to be accurate, requires endoscopy. The serum marker CRP has not proven sufficiently valuable as a marker for IBD specific inflammation. As an alternative, so far fecal calprotectin appears to be more reliable and has shown a certain value as predictive marker. Our preliminary data now show, that the serum concentrations of ficolin-2 are significantly higher in CD patients with a HBI >3. Ficolin-2 is a lectin and acute phase protein produced in the liver and, like MBL, can activate the lectin pathway of complement. Unlike MBL, deficiency for ficolin-2 was not detected in our patient cohort, nor could we find functional deficiencies for ficolin-2 (paper submitted).

Study Aims The study is aimed to substantiate the data from our pilot study which shows that ficolin-2 is significantly increased in CD patients during inflammation. Therefore, the study will measure ficolin-2 concentrations in a sufficiently large patient group to obtain enough statistical power and to compare these results with the endoscopic disease score (SES-CD) and CRP and calprotectin values. Statistical analysis of the data will show us if ficolin-2 is a reliable and easy to obtain new marker for active inflammation in CD.

Study Design Based on a power analysis 112 CD patients and 112 UC patients need to be analyzed. They will be recruited from Bern, Basel and Lausanne. Only patients with routine endoscopy will be included in the study and will be scored by SES-CD. Blood samples will be collected at the day of endoscopy. Stool sample will be collected within the same week of endoscopy. Calprotectin and CRP concentrations will be determined by routine diagnostics, ficolin-2 concentrations will be determined by ELISA in our laboratory. Finally, all data will be statistically analyzed.


Condition Intervention
Crohn Disease
Other: Endoscopy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease

Resource links provided by NLM:


Further study details as provided by University of Bern:

Primary Outcome Measures:
  • Ficolin-2 concentration in serum [ Time Frame: During endoscopy ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • CRP concentration in serum [ Time Frame: During endoscopy ] [ Designated as safety issue: No ]
  • Calprotectin in stool sample [ Time Frame: One week before endoscopy up to one week after endoscopy ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Serum Stool


Enrollment: 136
Study Start Date: October 2011
Study Completion Date: June 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Crohn's Disease patients
Other: Endoscopy
Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
2
Ulcerative colitis patients
Other: Endoscopy
Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.

  Hide Detailed Description

Detailed Description:

Background

Background Like mannan-binding lectin (MBL), ficolins are important soluble receptors for microbial associated molecular patterns leading to the activation of the lectin pathway complement. Ficolins are structurally related to MBL, but due to their different carbohydrate recognition domain represent an own family of lectins (1). The single polypeptide chains of ficolins form trimers and the trimers finally form higher order structures (tetramers up to hexamers) which constitute the functional protein. Humans have three ficolins: Ficolin-1 (M-ficolin), -2 (L-ficolin) and -3 (H-ficolin), whereas ficolin-2 and -3 are present in the serum, ficolin-1 is found on the surface of monocytes. Both, ficolin-2 and -3 are produced in the liver with an additional source for ficolin-3 in the lung. Like MBL, ficolins have to assemble with the MBL-associated serin proteases (MASPs) in order to activate the complement pathway (1). In our study on a possible role for the influence of the complement system in the development of CD-associated anti-Saccharomyces cerevisiae antibodies (ASCAs), we noticed that chronic inflammatory bowel disease (CIBD) patients, specifically Crohn's disease (CD) patients, exhibited high serum ficolin 2 concentrations.

Our research group is interested in the interaction of the innate immune system with microorganisms of the intestinal flora, focusing on possible defects in innate immune mechanisms. We have more than ten years experience in the field, with a special focus on ASCA and MBL. We have been able to continuously publish our work about these theories.

Our earlier and present studies on the role of MBL and the lectin pathway of complement in CD led to the finding of increased ficolin-2 concentration in the sera of CD patients. Moreover, we found that CD patients with a Harvey-Bradshaw index >3 had significantly higher ficolin 2 concentrations than those with a Harvey-Bradshaw index of ≤ 3.

Study Hypotheses

The following hypotheses are to be tested:

  1. The ficolin 2 concentration is higher in Crohn's patients with active disease than in CD patients in remission.
  2. Ficolin 2 correlates with endoscopic activity.
  3. Ficolin 2 correlates with calprotectin.

Objective

The findings from the first part of the study are to be confirmed in a prospective and more detailed study with a larger patient cohort, testing our (new) working hypothesis that ficolin 2 represents a serum marker for disease activity in CD.

Since it is currently difficult to reliably determine disease activity in CD patients using serum and stool markers without simultaneous endoscopic examination, another specific and easy to obtain disease marker which correlates well with disease activity would be highly welcome. Particularly because the current standard marker, to monitor disease activity (faecal calprotectin), is much less accepted than testing for parameters in the blood.

Therefore, the study aims at answering the question of whether ficolin 2 is present in greater concentrations in the blood of Crohn's patients with active inflammation compared to CD patients in remission or to ulcerative colitis (UC) patients.

Methods

For the purposes of the study, the endoscopic activity index will be recorded using the SES-CD (simplified endoscopic score for CD) for Crohn's patients and the Mayo score for colitis patients.

Approximately 5 ml blood will be taken to prepare serum. (5.5 ml or 4.9 ml S Monovette or 4.7 ml or 4.9 ml serum gel Monovette).

A second test tube of blood will be taken for CRP determination. In order to measure calprotectin, the patient will be asked to provide a stool sample shortly before or shortly after the endoscopic examination (within one week).

Serum ficolin values are measured by enzyme-linked immune sorbent assay (ELISA) in the laboratory at the Department of Clinical Research, University of Bern; all other values are determined in routine diagnostic laboratories.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

All CD and UC patients undergoing endoscopy for clinical reasons at one of the involved clinical centers.

Criteria

Inclusion Criteria:

  • known IBD
  • endoscopy for clinical reasons
  • enrolled in the Swiss IBD cohort study

Exclusion Criteria

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01473927

Locations
Switzerland
Gastroenterology and Hepatology, Basel University Hospital
Basel, Basel Stadt, Switzerland, 4031
Service de gastro-entérologie et hépatologie, CHUV Lausanne
Lausanne, Vaud, Switzerland, 1011
DCR, Gastroenterology, Bern, University of Bern
Bern, Switzerland, 3010
Sponsors and Collaborators
University of Bern
University Hospital, Basel, Switzerland
University of Lausanne Hospitals
Swiss IBD Cohort Study
MSD Merck Sharp & Dohme AG
Investigators
Study Director: Frank Seibold, Prof. Dr. med. Spital Tiefenau / Inselspital Bern
  More Information

Publications:
Responsible Party: Seibold Prof. Dr. med., Spital Tiefenau Bern / Inselspital Bern
ClinicalTrials.gov Identifier: NCT01473927     History of Changes
Other Study ID Numbers: 110/06
Study First Received: November 3, 2011
Last Updated: March 11, 2014
Health Authority: Switzerland: Ethikkommission

Keywords provided by University of Bern:
Inflammatory bowel diseases
Crohn disease
Ficolin-2
C-Reactive Protein
Calprotectin
Inflammatory markers
SES-CD

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Intestinal Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on August 21, 2014